MA-PRECISELY
7.12.2023 15:01:30 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced continued momentum for its Precisely Data Integrity Suite. The company has added dozens of customers spanning data integration, data governance, and geo addressing Suite services, with nearly half of global Suite sales attributed to new customer logos. Precisely is helping companies, such as Belfius Bank, Smiley Technologies, UK Power Networks, and Vantage Towers, to quickly build trust in the data they store in modern cloud and hybrid environments. These organizations use this data in AI, advanced analytics, and other high-value, data-driven initiatives to achieve greater operational efficiencies and improved business outcomes.
“In our ongoing commitment to make data easy to discover, understand and use reliably, we are procuring the Precisely Data Integrity Suite,” said Zachary Decent, Data Governance & Quality Manager, Enterprise Data Management at UK Power Networks, providing power to a quarter of the UK’s population. “This move signifies our dedication to fostering Data Best Practice principles, leveraging this platform to offer stakeholders an enriched experience through a comprehensive data catalog, with clearly defined data responsibilities and robust quality monitoring mechanisms.”
"Smiley's Analytics Services depend on a very high level of accuracy for address validation and location data,” said Chris Raper, Chief Strategy Officer, Smiley Technologies Inc., a provider of core banking software and services for community banks and financial institutions. “Leveraging Precisely Data Integrity Suite has allowed us to seamlessly integrate these services into our overall analytics solution supporting Community Banks.”
Research and consulting firm Gartner® identified data integrity as one of four themes in its recent Hype Cycle™ research1. According to the report, “AI relies on data, and better data leads to more reliable AI solutions. Without automated support, validating massive volumes of data is impossible.”
“We chose the Precisely Data Integrity Suite because it will provide us with a strong data governance framework that enables us to leverage trusted data across our organization,” said Sascha Glomski, Manager BI & Finance Transformation, Vantage Towers. “As one of the largest operators of mobile towers in Europe, having end-to-end visibility and a better understanding of our data will help us improve operations, reduce costs, and accelerate time to market.”
In addition to customer traction, Precisely added new partner certifications for the Data Integrity Suite this year. With the Suite, organizations can natively run data integrity processes at scale within leading data cloud environments, such as AWS Redshift, Databricks, Snowflake, and more, accelerating analytics where the data resides.
“Precisely allowed us to scale our integrated data governance and data quality program in order to reach our 2025 ambitions,” said Jérôme Sandron, Head of Data Governance at Belfius Bank, a leading Belgian banking and insurance group.
With the Precisely Data Integrity Suite, businesses harness trusted data to improve customer experiences, increase revenues, reduce costs, and mitigate risk. Comprising interoperable cloud services that share a common data catalog and user experience, the Suite gives organizations confidence their data, wherever it’s stored, has maximum accuracy, consistency, and context. The Data Integrity Suite includes Data Integration, Data Quality, Data Governance, Data Observability, Geo Addressing, Spatial Analytics, and Data Enrichment services.
“The strong customer momentum for the Data Integrity Suite confirms that it is essential to deliver cloud-native data integrity processing,” said Eric Yau, Chief Operating Officer at Precisely. “There is a need for trusted data, and we’re here to solve the complexities for business and data teams alike. We have extensive expertise to provide a clear path for businesses focused on achieving faster insights and optimal efficiencies for their organizations.”
Please visit the Precisely Data Integrity Suite page for more information about data integrity and its benefits.
GARTNER and HYPE CYCLE are a registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
1 Gartner, Hype Cycle for Emerging Technologies in Finance, 2023, July 11, 2023, Mark McDonald
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231207647047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom